

Interim report Q1 2022

28 April

Philipp Mathieu – Acting CEO and President



Forward Looking Statements

- IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information").
- The Information has been prepared and issued by the Company solely for use at the presentation held by the Company in relation to the Company's operations and position. The Information has not been independently verified and will not be updated. Unless otherwise stated, and any market data used in the Information is not attributed to a specific source, are estimates of the Company, and have not been independently verified. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.
- THE INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND BACKGROUND.
- The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities issued by the Company.
- The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





- Focus and strategic priorities
- Q1 operational and financial highlights
- Executing on commercialization and reimbursement

Fully focused on execution in Pancreatic Cancer



Incorporated 2017 in US, 2007 in Sweden

Listed on Nasdaq Stockholm under IMMNOV

Commercial in the US from August 2021

Exclusive laboratory in Marlborough, MA and HQ in Lund, Sweden

Build out position as front-runner in innovative early detection of pancreatic cancer

Revolutionizing early detection of pancreatic cancer and improving the survival rates

Successful commercial scale up in US

Execution of US reimbursement plan

Resources focused on pancreatic cancer

DISCOVERY, DEVELOPMENT AND VALIDATION

FULLY FOCUSED ON US MARKET PENETRATION AND COMMERCIAL EXECUTION

Large, unmet need for early diagnosis



Pancreatic cancer survival rates – 5 years

Timing of diagnosis – Today

5-9%



5-year survival in total

42%

5-year survival rate when diagnosed early (still localized, resectable)

3%

5-year survival rate when found late (metastatic, non-resectable)

Early Diagnosis:

<20%

found early enough to still be surgically addressable

Early detection enabled by Immunovia is key for saving lives



The front-runner in innovative pancreatic cancer testing

Best-in-class performance

89%

Sensitivity for early-stage cancer

92%

Sensitivity for all stages cancer

99% Specificity







- First-ever diagnostic test focused on early detection of pancreatic cancer in individuals at high risk for developing familial/hereditary pancreatic cancer
- First blood-based pancreatic cancer surveillance test available in USA
- Favorable performance and cost compared to current surveillance methods





Q1 – Operational highlights

- Peer-reviewed blinded validation study published in Clinical and Translation Gastroenterology
 - Independent validation of IMMray™ PanCan-d
 - Unmatched performance
- CAP accreditation of laboratory in the US
 - Opens up licensure in all US states including New York and California
- Further expertise added to the team
 - New CEO, CFO* and Head of IR
 - US leadership*
- PLA application* submitted

^{*} Early April 2022.





Priorities **Achievements** ✓ Publication of peer-reviewed validation Additional clinical validation for IMMray™ PanCan-d across risk groups study Strengthening US team for successful commercial scale up ✓ Hire of US Leader ✓ CAP Accreditation of Lab. Execution of US reimbursement plan for pancreatic cancer ✓ PLA code application filed ✓ Fully focus on Pancreatic Cancer and Roadmap to capture the potential of discovery programs in other indications programs deprioritized Prioritization for market access in non-US geographies





Q1 – Financial highlights

- Net sales of KSEK 182 (123)
 - Second quarter with IMMray[™] PanCan-d commercially available in the US
- Net earnings amounted to MSEK -44 (-23)
 - Focus on building business
 - Decrease in earnings due to R&D capitalization completed and increase in deprecation
- Solid cash position of MSEK 240 (425)

^{* (}x) same period as last year.



Continued focus on all pancreatic cancer risk groups


Risk group	Clinical evidence	Commercial	Next steps
Hereditary/ Familial	 Optimization study CMTS* Verification study Peer-reviewed validation study 	Yes	PanFAM-1 resultsAttain reimbursement
New onset diabetes	PanDIA-1 study (ongoing)	Not yet	• Finalize PanDIA-1
Symptomatic	 Optimization study CTMS* Verification study Improved performance study 	Not yet	Define clinical pathway after PanSYM-1

* Commercial Test Model Study (CTMS)



Executing reimbursement plan for US insurance coverage

Final publication of **peer-reviewed blinded validation study** in Clinical and Translational Gastroenterology journal¹



¹ Title: <u>Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from blood samples: Results of a multiplex biomarker signature validation study; Journal: Clinical and Translational Gastroenterology</u>





Physician experience program

- Selected pancreatic high-risk-surveillance centers
 - Limited number of no-charge-testing
 - Providers to become comfortable
- Broadly include IMMray[™] PanCan-d in standard testing routines
 - Developing Key Opinion Leaders advocates
- Imaging data generated for comparison

Drive Familiarity, Adoption and Reimbursement

Renewed management team





Philipp Mathieu CEO & President Immunovia AB



Karin Almqvist Liwendahl CFO



Jeff Borcherding CEO US



Tobias BülowSenior Director Investor
Relations & Corporate
Communications



Linda Mellby VP R&D



Lotta Blomgren Operations Director



Meagan Luipold Sales Director NA



Cindy Callahan Senior Marketing Director



Thomas KingMedical Director



Rolf Ehrnström Chief Scientific Officer



Hans Christian Pedersen VP Business Development



Annika Andersson QA/RA Director



Rob Pickles Market Access and Marketing Director



Collective Experience



- Corporate strategy, M&A and capital markets transactions in healthcare/life science
- Commercial experience in growing diagnostic businesses and healthcare brands in the US
- Leading and developing of business oriented financial functions
- International investor relations and corporate communications experience



US CEO – Jeff Borcherding

- Over 20 years of commercial leadership experience Healthcare and Software
 - Chief Marketing Officer Myriad Genetics
 - General Manager, Mental Health Myriad Genetics (formerly Assurex Health)
 - Brand Manager Procter and Gamble Pharmaceuticals
- My focus areas
 - Effective, scalable sales and marketing model in pancreatic cancer
 - Foundation for reimbursement
 - Internal capability and capacity





Fully focused and positioned for US market penetration and future growth

Mission of improving the survival rates of pancreatic cancer



- Best-in-class performing test
- First available dedicated test on the market



- Cost-efficient surveillance of high-risk
- On track for reimbursement



- Team with industry-leading competence
- Professional excellence and passion

Large
unmet and
growing
need for
early
diagnosis

Q&A

helloir@immunovia.com www.immunovia.com